The trial data which shows reduced rate of cognitive decline by 27 percent compared to placebo; further study to be done on side effects
Source : arabianbusiness.com
Read more…New Eisai-Biogen Alzheimer’s drug shows plenty of promise in Phase 3 clinical trial















